Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Devang P. Parikh"'
Autor:
Devang S. Parikh, MD, MA, Sarah Blissett, MD, MHPE, Kirsten Tolstrup, MD, Vaikom S. Mahadevan, MD
Publikováno v:
JACC: Case Reports, Vol 2, Iss 8, Pp 1089-1092 (2020)
We present this case of a 22-year-old woman with congenital heart disease as the youngest reported patient, to the best of our knowledge, to successfully undergo treatment of medically refractory torrential tricuspid regurgitation with the MitraClip
Externí odkaz:
https://doaj.org/article/1eb8fbfe409f4de593a0ec1d6070f62f
Autor:
Julia H Indik, Vineet Nair, Ruslan Rafikov, Iwan S Nyotowidjojo, Jaskanwal Bisla, Mayank Kansal, Devang S Parikh, Melissa Robinson, Anand Desai, Megha Oberoi, Akash Gupta, Taimur Abbasi, Zain Khalpey, Amit R Patel, Roberto M Lang, Samuel C Dudley, Bum-Rak Choi, Joe G N Garcia, Roberto F Machado, Ankit A Desai
Publikováno v:
PLoS ONE, Vol 11, Iss 10, p e0164526 (2016)
Sudden death is a leading cause of mortality in sickle cell disease, implicating ventricular tachyarrhythmias. Prolonged QTc on an electrocardiogram (ECG), commonly seen with myocardial ischemia, is a known risk for polymorphic ventricular tachycardi
Externí odkaz:
https://doaj.org/article/9f2a02da94f940d194963dbc14c1f793
Autor:
Chintan Y. Shah, Maulik R. Patel, Rahul J. Gupta, Raghav Sukhadiya, Deven Parmar, Heather Heading, Mukul R. Jain, Devang P. Parikh, Kinjal Barot, Harilal Patel, Hardik B. Patel, Nuggehally R. Srinivas, Vyom N. Dholakia, Kevinkumar Kansagra, Rajendrakumar H. Jani, Krupi Parmar, Jason Lickliter
Publikováno v:
Clinical Pharmacokinetics
This phase I study of ZYAN1 was conducted to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers. The study was a randomized, double-blind, placebo-controlled phase I study carried out in two pa
Autor:
Krupi Parmar, Kevinkumar Kansagra, Devang P. Parikh, Hardik B. Patel, Maulik R. Patel, Harilal Patel, Jaimik A. Patel, Uday S. Patil, Deven Parmar, Nuggehally R. Srinivas, Mayur M. Soni, Swagat S. Gujarathi
Publikováno v:
Clinical drug investigation. 38(1)
Peroxisome proliferator-activated receptors (PPARs) have recently become a focus of interest for their important roles in glucose and lipid metabolism. In humans, PPARα activation causes a decrease in plasma triglyceride (TG) levels, enhancement of